Development of an in situ- forming systems for vancomycin delivering:The role of drug hydrophilicity
Paper ID : 1195-MST2015-FULL
mina darestani-farahani1, Hamid Mobedi *2, Ebrahim Vasheghani-Farahani1, fariba ganji1
1tarbiat modares university
2Iran Polymer and Petrochemical Institute
In situ forming drug delivery systems consist of a solution of the drug and PLGA dissolved in a biocompatible solvent. After injection into the body, solvent diffuses into the tissue fluid, leading to polymer precipitation and the formation of a solid implant. In situ forming implant systems avoid the complex fabrication process of microparticles, have no drug loss during the preparation, and ease of scale-up.
Polymer solution delivery platforms can provide prolonged release of biopharmaceutical agents while offering a greater ease of administration than surgically implanted systems . Delivery is affected by injection directly into the patient. Since the polymer is water-insoluble, contact with the aqueous-based physiologic surroundings causes the solution to undergo liquid de-mixing to produce a two-phase, gelled implant. As a result, the formation of the polymer membrane carrier takes place in vivo, simultaneously with the release of the incorporated drug. Since the objective is to maintain drug delivery Within a specified therapeutic window, this usually implies minimizing the initial burst and achieving prolonged, zero-order release rate over the it’s lifetime.
The aim of this study was investigating the effect of druf hydrophilicity on the morphology and release rate of prepared formulation.
SEM result showed that with increasing hydrophilicity of vancomycoin the size and amount of pores increased due to increasing the rate of solvent- non solvent exchange in phase inversion process and as result initial burst release are increased.
vancomycin, in situ- forming,hydrophilicity
Status : Paper Accepted (Poster Presentation)